ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026GlobeNewsWire • 11/06/26
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?Zacks Investment Research • 10/21/26
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales ResultsGlobeNewsWire • 10/12/26
ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2Zacks Investment Research • 08/27/26
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026GlobeNewsWire • 08/13/26
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026GlobeNewsWire • 08/06/26
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales ResultsGlobeNewsWire • 07/09/26
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026GlobeNewsWire • 05/14/26
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026GlobeNewsWire • 05/07/26
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCellZacks Investment Research • 04/22/26
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent DirectorsGlobeNewsWire • 04/13/26
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales ResultsGlobeNewsWire • 04/08/26
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to BoardGlobeNewsWire • 03/18/26
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025GlobeNewsWire • 03/04/26